RT Journal Article
SR Electronic
T1 Is coagulation-protein consumption upon admission linked to COVID-19 severity and mortality?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.19.21255747
DO 10.1101/2021.04.19.21255747
A1 Francisco C. Ceballos
A1 Pablo Ryan
A1 Rafael Blancas Gómez-Casero
A1 María Martin-Vicente
A1 Erick Joan Vidal-Alcántara
A1 Felipe Peréz-García
A1 Sofía Bartolome
A1 Juan Churruca-Sarasqueta
A1 Ana Virseda-Berdices
A1 Oscar Martínez-González
A1 Oscar Brochado-Kith
A1 Marta Rava
A1 Carolina Vilches-Medkouri
A1 Natalia Blanca-López
A1 Ignacio Ramirez Martinez-Acitores
A1 Patricia Moreira-Escriche
A1 Carmen De Juan
A1 Salvador Resino
A1 Amanda Fernández-Rodríguez
A1 María Ángeles Jiménez-Sousa
YR 2021
UL http://medrxiv.org/content/early/2021/04/20/2021.04.19.21255747.abstract
AB The link between coagulation system disorders and COVID-19 has not yet been fully elucidated. With the aim of evaluating the association of several coagulation proteins with COVID-19 severity and mortality, we performed a cross-sectional study in 134 patients classified according to the highest disease severity reached during the disease. We found higher levels of antithrombin, prothrombin, factor XI, factor XII and factor XIII in asymptomatic/mild and moderate COVID-19 patients than healthy individuals. Interestingly, decreased levels of antithrombin, factor XI, XII and XIII were observed in those patients who eventually developed severe illness. Additionally, survival models showed us that patients with lower levels of these coagulation proteins had an increased risk of death. In conclusion, COVID-19 provokes early increments of some specific coagulation proteins in most patients. However, lower levels of these proteins at diagnosis might “paradoxically” imply a higher risk of progression to severe disease and COVID-19-related mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant number COV20/1144 [MPY224/20] to AFR/MAJS). AFR, MAJS and MR are Miguel Servet researchers supported and funded by ISCIII (grant numbers: CP14CIII/00010 to AFR, CP17CIII/00007 to MAJS and CP19CIII/00002 to MR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Ethics Committee of the Institute of Health Carlos III (PI 33_2020-v3) and the Ethics Committee of each hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Availability on request.